Document and Entity Information Document Information [Table] Document Information [Line Items] Document and Entity Information Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Condensed Consolidated Balance Sheets Statement [Table] Statement [Line Items] Statement Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Operating Lease, Right-of-Use Asset Right-of-use asset Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and stockholders' equity Current liabilities Current liabilities Accounts Payable, Current Accounts payable Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to clinical costs. Accrued Liabilities, Clinical Trial, Current Clinical trial accrued liabilities Amount of accrued expenses and liabilities classified as other, due within one year or the normal operating cycle, if longer. Accrued Expenses And Other Liabilities, Current Accrued expenses and other current liabilities Total Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current As of ending balance As of beginning balance Warrant liabilities Other Liabilities, Current Related party payable Other Liability, Current, Related Party [Extensible Enumeration] Operating Lease, Liability, Current Lease liability, short-term Liabilities, Current Total current liabilities Operating Lease Liability, Noncurrent Lease liability, long-term Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 6) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity Preferred Stock, Value, Issued Preferred stock, $0.001 par value per share; 10,000,000 shares authorized and no shares issued or outstanding as of June 30, 2026 and December 31, 2025 Common Stock, Value, Issued Common stock, $0.001 par value per share, 100,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 6,575,656 and 2,308,294 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Balance at end of period Balance at beginning of period Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Balance at end of period (in shares) Balance at beginning of period (in shares) Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations Operating Expenses [Abstract] Operating expenses Research and Development Expense Research and development Total research and development General and Administrative Expense General and administrative Total general and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Loss from operations Other Nonoperating Income (Expense) [Abstract] Other income (expense) Fair Value Adjustment of Warrants (Loss) gain from change in fair value of warrant liabilities Gain from change in fair value of warrant liabilities Interest Income (Expense), Net Interest income, net Other Expenses Total other income Total other income Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Income Tax Expense (Benefit) Provision for income taxes Benefit for income taxes Net loss Net loss Net loss Earnings Per Share, Basic and Diluted [Abstract] Loss per share: Earnings Per Share, Basic Loss per share of common stock, basic (in dollars per share) Loss per share of common stock, basic (in dollars per share) Earnings Per Share, Diluted Loss per share of common stock, diluted (in dollars per share) Loss per share of common stock, diluted (in dollars per share) Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Weighted average shares of common stock outstanding: Weighted Average Number of Shares Outstanding, Basic Weighted average shares of common stock, basic (in shares) Weighted average shares of common stock, basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average shares of common stock, diluted (in shares) Weighted average shares of common stock, diluted (in shares) Condensed Consolidated Statements of Changes in Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock Common Stock Additional Paid-in Capital Additional Paid-in Capital Accumulated Deficit Accumulated Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Amount of common stock and warrants issued during the period. Stock Issued During Period, Value, Common Stock and warrants Issuance of common stock and warrants in connection with an underwritten public offering, net of issuance costs Number of common stock and warrants issued during the period. Stock Issued During Period, Shares, Common Stock and warrants Issuance of common stock and warrants in connection with an underwritten public offering, net of issuance costs (in shares) Amount of common stock and pre-funded warrants issued during the period. Stock Issued During Period, Value, Common Stock And Pre-funded Warrants Issuance of common stock and pre-funded warrants, net of issuance costs Number of common stock and pre-funded warrants issued during the period. Stock Issued During Period, Shares, Common Stock And Pre-funded Warrants Issuance of common stock and pre-funded warrants, net of issuance costs (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock under an at the market offering agreement, net of issuance costs Common Stock Issued Issuance of common stock (in shares) Issuance of common stock under an at the market offering agreement, net of issuance costs (in shares) Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Underwritten public offering issuance costs Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock for exercise of warrants Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of common stock for exercise of warrants (in shares) Restricted Stock, Value, Shares Issued Net of Tax Withholdings Issuance of common stock for vested restricted stock units, net of shares withheld for withholding taxes Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Issuance of common stock for vested restricted stock units, net of shares withheld for withholding taxes (in shares) Stock Issued During Period, Value, Issued for Services Issuance of common stock for professional services Stock Issued During Period, Shares, Issued for Services Issuance of common stock for professional services (in shares) Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Issuance of common stock for vested restricted stock units Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of common stock for vested restricted stock units (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation The amount of issuance costs related to stock and warrants. Stock And Warrants Issuance Costs Stock and warrants issuance costs The amount of issuance costs related to stock and pre-funded warrants. Stock And Pre-Funded Warrants Issuance Costs Stock and pre-funded warrants issuance costs The amount of issuance costs related to at the market offering agreement. Stock Issuance Cost, At The Market Offering Agreement Net of issuance costs Condensed Consolidated Statements of Cash Flows Sale of Stock [Axis] Sale of Stock [Domain] Private Placement [Member] Private Placement Private placement offering Overallotment Underwritten public offering Represents the information pertaining to at-the market offering agreement. At The Market Offering Agreement [Member] At the market offering Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation. Stock-based compensation Amount of non cash professional services expenses recognized during the period. Non Cash Professional Services Expense Non-cash professional services expenses Amount of non-cash lease (credit) charge. Non Cash Lease (Credit) Charge Non-cash lease charge (credit) Depreciation Depreciation Increase (Decrease) in Operating Capital [Abstract] Change in operating assets and liabilities Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued and other liabilities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investing activities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net cash provided by (used in) investing activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Financing activities The cash inflow from the additional capital contribution to the entity and from issuance of rights to purchase common shares at predetermined price. Proceeds From Issuance Of Common Stock And Warrants Proceeds from the issuance of common stock and warrants under the securities purchase agreements from a private placement offering Proceeds from Issuance or Sale of Equity Proceeds from the issuance of common stock and warrants under an underwritten public offering Payments of Stock Issuance Costs Payment of issuance costs in connection with the sale of common stock Offering expenses Proceeds from Issuance of Common Stock Proceeds from the issuance of common stock under an at the market offering agreement Proceeds from Warrant Exercises Proceeds from exercise of warrants Payment, Tax Withholding, Share-Based Payment Arrangement Payment of employee withholding taxes related to shares withheld from vested restricted stock units Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental non-cash investing and financing transactions Future cash outflow to pay for deferred issuance costs that have occurred. Deferred Issuance Costs Incurred But Not Yet Paid Unpaid issuance costs Business, basis of presentation, new accounting standards and summary of significant accounting policies Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Business, basis of presentation, new accounting standards and summary of significant accounting policies Prepaid expenses and other current assets The entire disclosure for prepaid expense and other current assets at the end of the reporting period. Prepaid Expense And Other Current Assets [Text Block] Prepaid expenses and other current assets Property and equipment, net Property, Plant and Equipment Disclosure [Text Block] Property and equipment, net The entire disclosure for current liabilities at the end of the reporting period. Current liabilities [Text Block] Current liabilities Related party Related Party Transactions Disclosure [Text Block] Related party Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies Stockholders' equity Stock, Class of Stock [Table] Class of Stock [Line Items] Stockholders' Equity Note Disclosure [Text Block] Stockholders' equity Significant segment expenses and loss before income taxes Segment Reporting Disclosure [Text Block] Significant segment expenses and loss before income taxes Income taxes Income Tax Disclosure [Text Block] Income taxes Loss per share of common stock Earnings Per Share [Text Block] Loss per share of common stock Fair value of financial instruments Fair Value Disclosures [Text Block] Fair value of financial instruments Basis of Presentation and Significant Accounting Policies [Text Block] Basis of presentation New Accounting Pronouncements, Policy [Policy Text Block] New accounting standards Use of Estimates, Policy [Policy Text Block] Estimates and assumptions Disclosure of accounting policy for financial instruments with characteristics of both liabilities and equity. Financial Instruments, Liabilities And Equity Policy [Policy Text Block] Financial Instruments with Characteristics of Both Liabilities and Equity Deferred Costs Capitalized Prepaid And Other Assets [Table Text Block] Schedule of prepaid expenses and other current assets Property, Plant and Equipment [Table Text Block] Schedule of property and equipment, net Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses and other current liabilities Financial Instruments Subject to Mandatory Redemption Disclosure [Table Text Block] Schedule of warrant liabilities Tabular disclosure of warrants exercised. Schedule OF Warrant Exercised [Table Text Block] Schedule of warrants exercised Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of outstanding warrants Share-Based Payment Arrangement, Activity [Table Text Block] Schedule of outstanding awards issued pursuant to our stock-based award plans and inducement plan Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of restricted stock units ("RSUs") and related transactions Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock-based compensation expense Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of significant segment expenses Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of basic and diluted loss per share of common stock Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of outstanding securities which were not included in the calculation of diluted earnings per share of common stock Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Schedule of fair value measurements on a recurring basis Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Business, basis of presentation, new accounting standards and summary of significant accounting policies Stockholders' equity Prepaid Insurance Insurance Deposits Assets, Current Deposits Deferred Offering Costs Deferred equity offering costs Other Prepaid Expense, Current Other prepaid expenses Property, Plant and Equipment, Gross Office equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Amount of increase (decrease) in obligations incurred and payable, pertaining to clinical costs. Increase (Decrease) in Accrued Liabilities Clinical Trial Current Amount of clinical trial accrued liabilities increased, due to timing of third-party clinical research organization invoices for services performed Employee-related Liabilities, Current Employee related costs Accrued Professional Fees, Current Professional service fees Other Accrued Liabilities, Current Other Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Gain from change in fair value of warrant liabilities Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Class of Warrant or Right [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information pertaining to series B warrants issued in November 2022. November 2022 Series B [Member] November 2022 Series B Class of Warrant or Right [Line Items] Warrant liabilities Warrants Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of warrants per unit Exercise Price of Warrants or Rights Exercise Price Warrants exercise price Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Axis] Related Party Transaction [Domain] Represents the information pertaining to Shared Services Agreement. Shared Services Agreement Shared Services Agreement Related Party Transaction [Line Items] Related party Other Liability, Current, Related Party, Name [Extensible Enumeration] Amount payable to related party under extended payment terms. Related Party, Extended Payment Liability Extended terms payable Amount payable to related party under extended payment terms. Related Party Extended Payment Liability Payable Extended terms amount to be paid on June 30, 2026 Amount payable to related party under extended payment terms due in three months. Related Party, Extended Payment Liability, Payable in Three Months Extended terms amount to be paid on September 30, 2026 Accrued interest payable to related party under extended payment terms. Related Party, Accrued Interest Payable Extended terms, Accrued interest payable Related Party Transaction, Rate Fixed interest rate Accrued liability payable to related party for clinical trial services. Related Party, Clinical Trial Accrued Liability Amount payable in clinical trial accrued liabilities Asset Acquisition [Table] Asset Acquisition [Line Items] Contractual Obligation Contingent liabilities recorded Gain Contingency, Unrecorded Amount Contingent assets recorded Subsequent Event [Table] Represents the information pertaining to pre-funded warrants. Pre-Funded Warrants [Member] Pre-Funded Warrants Represents information pertaining to series C warrant. Series C Warrant [Member] Series C warrants Represents information pertaining to series D warrant. Series D Warrant [Member] Series D warrants The underwritten 2026 public offering. Public Offering 2026 [Member] 2026 public offering Class of Stock [Axis] Class of Stock [Domain] Represents the information pertaining to Class A Units, each consisting of one share of Class A Common Stock and one Warrant [Member] Class A Units [Member] Class A units Represents the information pertaining to Class B Units, each Class B Unit consisting of one share of Series B Convertible Preferred Stock, convertible into one share of common stock, one Series A Warrant and one Series B Warrant. Class B Units [Member] Class B units Sale of Stock, Consideration Received on Transaction Net proceeds The number of common stock per units issued under the arrangement. Number Of Common Stock Issued Per Unit Number of common stock per unit The number of warrants per units issued under the arrangement. Number Of Warrants Issued Per Unit Number of warrants issued per unit Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants to purchase shares of common stock Shares Issued, Price Per Share Original issue price, per share Offering shares (Per share) Represents the warrants issued through pre-funded warrants scheme in January 2026 with exercise price $ 0.0010. January 2026 Pre-Funded, Warrant Exercise Price 0.0010 [Member] January 2026 Pre-Funded, Warrant Exercise Price 0.0010 January 2026 Pre-funded Represents the warrants issued through Series C warrants scheme in January 2026 with exercise price $ 3.1000. January 2026 Series C, Warrant Exercise Price 3.1000 [Member] January 2026 Series C, Warrant Exercise Price 3.1000 January 2026 Series C Represents the warrants issued through Series D warrants scheme in January 2026 with exercise price $ 3.1000. January 2026 Series D, Warrant Exercise Price 3.1000 [Member] January 2026 Series D, Warrant Exercise Price 3.1000 January 2026 Series D Number of warrants exercised in shares. Stock Issued During Period Shares Warrants Exercised, Shares Total exercised warrants Related Party [Axis] Related Party [Domain] Related Party [Member] Related party Location, Statement of Income, Balance [Axis] The amount of maximum aggregate offering price. Maximum Aggregate Offering Price Maximum aggregate offering price Percentage of sales agent commission. Percentage Of Sales Agent Commission Percentage of sales agent commission Aggregate amount of common shares reserved for future issuance. Common Stock, Capital Reserved for Future Issuance Common stock capital reserved for future issuance The net cash inflow from issuance of stock and pre-funded warrants. Proceeds From Issuance Of Stock And Prefunded Warrants Issuance of common stock and pre-funded warrants Amount of cash outflow made during the period for placement agent fees in connection with the offering. Payments For Placement Agent Fees Cash fee payment to the placement agent Class of Warrant or Right, Number of Warrants Issued Number of Warrants Issued Number of pre-funded warrants Professional Fees Record of operating expenses Represents the warrants with exercise price $15,919.20. Warrants Exercise Price 15,919.20 [Member] Warrants Exercise Price 15,919.20 Represents information pertaining to November 2022 Series B warrants with exercise price of $ 0.00. November 2022 Series B Warrant Exercise Price 0.00 [Member] November 2022 Series B Warrant Exercise Price 0.00 Represents the warrants issued through placement agents in June 2024 with exercise price $ 54.0375. June 2024 Placement Agent, Warrant Exercise Price 54.0375 [Member] June 2024 Placement Agent, Warrant Exercise Price 54.0375 Represents the warrants issued as series B in June 2024 with exercise price $ 43.23. June 2024 Series B, Warrant Exercise Price 43.23 [Member] June 2024 Series B, Warrant Exercise Price 43.23 Warrant liabilities Warrants Class of Warrant or Right, Outstanding Number of Warrants The threshold period following the public announcement of the Company receiving positive Phase 1 multiple ascending dose ("MAD") data for expiry of warrants. Threshold Period Following the Public Announcement of Receiving Positive Phase 1 Multiple Ascending Dose Data For Expiry of Warrants Threshold period following the public announcement of receiving positive phase 1 multiple ascending dose data for expiry of warrants Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Represents the information pertaining to 2022 plan. Stock Plan 2022 [Member] 2022 Plan Represents the information pertaining to first amendment to the 2022 Plan (the "First Amendment"). First Amendment To Stock Plan 2022 [Member] 2022 Plan (the "First Amendment") Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation The period over which the shares reserved for further issuance under share based compensation will increase annually. Share-based Compensation Arrangement by Share-based Payment Award, Period Number of shares reserved for further issuance Increase Annually Period of automatic increase in shares reserved Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Percentage of the common shares outstanding (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Number of shares added (in shares) Stock options Restricted Stock Units (RSUs) [Member] RSUs Represents the information pertaining to 2019 stock plan. 2019 Plan 2019 Plan Represents the information pertaining to 2021 stock plan. 2021 Inducement Plan 2021 Inducement Plan Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Shares of Common Stock Issuable for Options, Outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number RSU's Fair value, Ending balance (in shares) RSU's Fair value, Beginning balance (in shares) RSUs Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Remaining shares of common stock available for future issuance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period RSU's, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period RSU's, Number Vested and Released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value RSU's Fair value, Ending balance (per share) RSU's Fair value, Opening balance (per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value RSU's Fair value, Granted (per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value RSU's Fair value, Vested and released (per share) Fair value of outstanding award under share-based payment arrangement. Excludes share and unit options. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Fair Value, Outstanding Balance Outstanding, Aggregate Fair Value, ending balance Outstanding, Aggregate Fair Value, beginning balance Fair value of outstanding award under share-based payment arrangement. Excludes share and unit options. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Fair Value, Outstanding Outstanding, Aggregate Fair Value, Vested and released The number of vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Number Shares of Common Stock Issuable for RSUs, Vested and Deferred Release (in shares) Per share or unit weighted-average fair value of vested award under share-based payment arrangement. Excludes share and unit options. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Grant Date Fair Value Average Grant Date Fair Value Price , Vested and Deferred Release (per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Aggregate Intrinsic Value, Vested and Deferred Release Represents the information pertaining to Stock Plans 2019, 2022 And Inducement Plan. Stock Plan 2019, 2022 And Inducement Plan [Member] Stock-based award plans Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-based Payment Arrangement, Expense Stock-based compensation Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized share-based compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Unrecognized share-based compensation - Weighted average period Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Domain] Represents the information pertaining to a single reportable segment. Single Reportable Segment [Member] Single reportable segment Segment Reporting Information [Line Items] Significant segment expenses Number of Reportable Segments Number of reportable segments Research and Development Expense [Abstract] Research and development Amount of expenses incurred in the first clinical trial program associated with research and development. Research and Development Expense, First Clinical Trial Program Direct costs - Vanoglipel Amount of expenses incurred in the second clinical trial program associated with research and development. Research and Development Expense, Second Clinical Trial Program Direct costs - DA-1726 Other Research and Development Expense Direct costs - Other R&D The amount of expense provided in the period for labor and related services incurred in Research and development. Labor And Related Expense, Research And Development Indirect costs - Employee compensation and benefits The amount of expense provided in the period for consultancy services incurred in Research and development. Consulting Fee, Research And Development Indirect costs - Consulting General and Administrative Expense [Abstract] General and administrative The amount of expense provided in the period for legal costs and professional costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. Legal And Professional Fees Legal and professional fees The amount of expense provided in the period for consultancy services incurred in General and administrative. Consulting Fee, General And Administrative Consulting The amount of expense provided in the period for labor and related services incurred in General and administrative. Labor And Related Expense, General And Administrative Employee compensation and benefits Other General and Administrative Expense Other G&A Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrants Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Loss per share of common stock Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Outstanding securities not included in the calculation of diluted earnings per share of common stock (in shares) Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Recurring Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Level 1 Level 1 Level 2 Level 2 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value of financial instruments Assets, Fair Value Disclosure [Abstract] Assets Cash and Cash Equivalents, Fair Value Disclosure Bank money market funds Assets, Fair Value Disclosure Total assets at fair value Liabilities, Fair Value Disclosure [Abstract] Liabilities Fair value of financial and nonfinancial obligations for warrant liabilities. Warrant Liabilities, Fair Value Disclosure Warrant liabilities Liabilities, Fair Value Disclosure Total liabilities at fair value